Company provides preliminary 2025 guidance and advance notification of a proposed financing transaction to provide a $30 million unsecured promissory note.
P3 Health Partners Inc., a patient-centered, physician-led population health management company, is targeting profitability in 2025, with initial revenue guidance for the year of $1.350 billion to $1.500 billion and Adjusted EBITDA of negative ($35) million to $5 million.
“Management’s Discussion and Analysis of Financial Condition and Results of Operations”
“The execution of our previously announced $130+ million EBITDA growth initiatives is going as planned, most of which have been actioned and implemented. Given our progress, we are targeting to be profitable in 2025. Additionally, we have highly supportive shareholders and the contemplated financing will provide adequate liquidity to fund expected working capital needs,” said Aric Coffman, CEO of P3. “Our business model remains fundamentally strong as we continue to drive value for our PCP partners, payors, and patients. We intend to issue full 2025 guidance at the time when we report our fourth quarter 2024 earnings results.”
Health Technology Insights: BioMérieux Launches GENE-UP TYPER: Rapid Listeria Contamination Analysis for Food Industry
The Company is currently engaged in discussions with its largest shareholder for a proposed financing transaction to provide an additional $30 million unsecured promissory note and warrants, on terms that are expected to be similar to the financing transaction completed in December 2024. Any financing transaction remains subject to the approval of a committee of independent, disinterested directors of the Company and the negotiation and execution of definitive documentation.
Health Technology Insights: Glytec Advances Market Leadership in Critical Time for the Hospital Industry
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities. Any securities offered by the Company will not be and have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Health Technology Insights: Kyruus Health & Abundant Health Partner to Enhance Patient Access & Engagement
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source: Businesswire
